Foghorn Therapeutics Inc. (FHTX) Earnings History
Annual and quarterly earnings data from 2018 to 2025
Loading earnings history...
FHTX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
FHTX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 89.2% | -265.6% | -240.3% |
| 2024 | 100.0% | -454.3% | -383.2% |
| 2023 | 100.0% | -315.9% | -288.2% |
| 2022 | 100.0% | -609.2% | -566.3% |
| 2021 | 100.0% | -7637.1% | -7681.6% |
Download Data
Export FHTX earnings history in CSV or JSON format
Free sign-in required to download data
Foghorn Therapeutics Inc. (FHTX) Earnings Overview
As of May 9, 2026, Foghorn Therapeutics Inc. (FHTX) reported trailing twelve-month net income of -$74M, reflecting +25.3% year-over-year growth. The company earned $-1.18 per diluted share over the past four quarters, with a net profit margin of -240.3%.
Looking at the long-term picture, FHTX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$26M in fiscal 2018.
Foghorn Therapeutics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RVMD (-$1.37B net income), TNGX (-$102M net income, -162.9% margin), VYNE (-$26M net income, -4646.1% margin), FHTX has comparable earnings metrics. Compare FHTX vs RVMD →
FHTX Earnings vs Peers
Earnings metrics vs comparable public companies
FHTX Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$74M | +14.2% | -$82M | $-1.18 | -240.3% | -265.6% |
| 2024 | -$87M | +12.0% | -$103M | $-1.58 | -383.2% | -454.3% |
| 2023 | -$98M | +9.6% | -$108M | $-2.34 | -288.2% | -315.9% |
| 2022 | -$109M | -7.5% | -$117M | $-2.62 | -566.3% | -609.2% |
| 2021 | -$101M | -47.3% | -$101M | $-2.78 | -7681.6% | -7637.1% |
| 2020 | -$69M | -34.6% | -$69M | $-1.90 | -16000.0% | -15937.4% |
| 2019 | -$51M | -94.1% | -$51M | $-1.40 | - | - |
| 2018 | -$26M | - | -$26M | $-1.34 | - | - |
See FHTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs FHTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare FHTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonFHTX — Frequently Asked Questions
Quick answers to the most common questions about buying FHTX stock.
Is FHTX growing earnings?
FHTX EPS is $-1.18, with earnings growth accelerating to +25.3%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-74M.
What are FHTX's profit margins?
Foghorn Therapeutics Inc. net margin is -240.3%, with operating margin at -265.6%. Below-average margins reflect competitive or cost pressures.
How consistent are FHTX's earnings?
FHTX earnings data spans 2018-2025. The accelerating earnings trend is +25.3% YoY. Historical data enables comparison across business cycles.